5-リポキシゲナーゼ活性タンパク質阻害剤のパイプライン・インサイト2017

◆英語タイトル:5-Lipoxygenase Activating Protein (FLAP) Inhibitors -Pipeline Insights, 2017
◆商品コード:DIMR201627
◆発行会社(調査会社):DelveInsight
◆発行日:2017年11月
◆ページ数:約60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。
本調査レポートでは、世界における5-リポキシゲナーゼ活性タンパク質阻害剤のパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・5-リポキシゲナーゼ活性タンパク質阻害剤の概要
・5-リポキシゲナーゼ活性タンパク質阻害剤のパイプライン概要
・企業別開発中の5-リポキシゲナーゼ活性タンパク質阻害剤
・後期治験段階の薬剤(Filed & Phase III):比較分析
・中期治験段階の薬剤(Phase II):比較分析
・初期治験段階の薬剤(Phase I & IND Filed):比較分析
・薬剤候補のプロファイル
・5-リポキシゲナーゼ活性タンパク質阻害剤の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・5-リポキシゲナーゼ活性タンパク質阻害剤開発に取り組んでいる企業リスト
・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “5-Lipoxygenase Activating Protein (FLAP) Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the 5-Lipoxygenase Activating Protein (FLAP) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for 5-Lipoxygenase Activating Protein (FLAP) Inhibitors. DelveInsight’s Report also assesses the 5-Lipoxygenase Activating Protein (FLAP) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of 5-Lipoxygenase Activating Protein (FLAP) Inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the 5-Lipoxygenase Activating Protein (FLAP) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for 5-Lipoxygenase Activating Protein (FLAP) Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Overview
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Disease Associated
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Pipeline Therapeutics
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Therapeutics under Development by Companies
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Filed and Phase III Products
• Comparative Analysis
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Phase II Products
• Comparative Analysis
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Phase I and IND Filed Products
• Comparative Analysis
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors – Discontinued Products
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for 5-Lipoxygenase Activating Protein (FLAP) Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for 5-Lipoxygenase Activating Protein (FLAP) Inhibitors by Therapy Area, 2017
• Number of Products under Development for 5-Lipoxygenase Activating Protein (FLAP) Inhibitors, 2017
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2017
• Comparative Analysis Phase II Products, 2017
• Comparative Analysis Phase I and IND Filed Products, 2017
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
• Drug Candidates Profiles
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Monotherapy Products
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Combination Products
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Route of Administration
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Stage and Route of Administration
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Molecule Type
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Stage and Molecule Type
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Therapeutics – Discontinued Products
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2017


List of Figures
• Number of Products under Development for 5-Lipoxygenase Activating Protein (FLAP) Inhibitors by Therapy Area, 2017
• Number of Products under Development for 5-Lipoxygenase Activating Protein (FLAP) Inhibitors, 2017
• Filed and Phase III Products, 2017
• Phase II Products, 2017
• Phase I and IND Filed Products, 2017
• Discovery and Pre-Clinical Stage Products, 2017
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Monotherapy Products
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Combination Products
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Route of Administration
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Stage and Route of Administration
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Molecule Type
• 5-Lipoxygenase Activating Protein (FLAP) Inhibitors Assessment by Stage and Molecule Type


【レポートのキーワード】

5-リポキシゲナーゼ活性タンパク質阻害剤、医薬品、製薬、研究開発、パイプライン、治療、治験

★調査レポート[5-リポキシゲナーゼ活性タンパク質阻害剤のパイプライン・インサイト2017] (コード:DIMR201627)販売に関する免責事項を必ずご確認ください。
★調査レポート[5-リポキシゲナーゼ活性タンパク質阻害剤のパイプライン・インサイト2017]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆